Literature DB >> 33484118

Long-term evolution of multiple sclerosis iron rim lesions in 7 T MRI.

Assunta Dal-Bianco1, Günther Grabner1,2, Claudia Kronnerwetter3, Michael Weber3, Barbara Kornek1, Gregor Kasprian3, Thomas Berger1, Fritz Leutmezer1, Paulus Stefan Rommer1, Siegfried Trattnig3, Hans Lassmann4, Simon Hametner1.   

Abstract

Recent data suggest that multiple sclerosis white matter lesions surrounded by a rim of iron containing microglia, termed iron rim lesions, signify patients with more severe disease course and a propensity to develop progressive multiple sclerosis. So far, however, little is known regarding the dynamics of iron rim lesions over long-time follow-up. In a prospective longitudinal cohort study in 33 patients (17 females; 30 relapsing-remitting, three secondary progressive multiple sclerosis; median age 36.6 years (18.6-62.6), we characterized the evolution of iron rim lesions by MRI at 7 T with annual scanning. The longest follow-up was 7 years in a subgroup of eight patients. Median and mean observation period were 1 (0-7) and 2.9 (±2.6) years, respectively. Images were acquired using a fluid-attenuated inversion recovery sequence fused with iron-sensitive MRI phase data, termed FLAIR-SWI, as well as a magnetization prepared two rapid acquisition gradient echoes, termed MP2RAGE. Volumes and T1 relaxation times of lesions with and without iron rims were assessed by manual segmentation. The pathological substrates of periplaque signal changes outside the iron rims were corroborated by targeted histological analysis on 17 post-mortem cases (10 females; two relapsing-remitting, 13 secondary progressive and two primary progressive multiple sclerosis; median age 66 years (34-88), four of them with available post-mortem 7 T MRI data. We observed 16 nascent iron rim lesions, which mainly formed in relapsing-remitting multiple sclerosis. Iron rim lesion fraction was significantly higher in relapsing-remitting than progressive disease (17.8 versus 7.2%; P < 0.001). In secondary progressive multiple sclerosis only, iron rim lesions showed significantly different volume dynamics (P < 0.034) compared with non-rim lesions, which significantly shrank with time in both relapsing-remitting (P < 0.001) and secondary progressive multiple sclerosis (P < 0.004). The iron rims themselves gradually diminished with time (P < 0.008). Compared with relapsing-remitting multiple sclerosis, iron rim lesions in secondary progressive multiple sclerosis were significantly more destructive than non-iron rim lesions (P < 0.001), reflected by prolonged lesional T1 relaxation times and by progressively increasing changes ascribed to secondary axonal degeneration in the periplaque white matter. Our study for the first time shows that chronic active lesions in multiple sclerosis patients evolve over many years after their initial formation. The dynamics of iron rim lesions thus provide one explanation for progressive brain damage and disability accrual in patients. Their systematic recording might become useful as a tool for predicting disease progression and monitoring treatment in progressive multiple sclerosis.
© The Author(s) (2021). Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  iron rims; multiple sclerosis; smoldering lesions

Mesh:

Substances:

Year:  2021        PMID: 33484118     DOI: 10.1093/brain/awaa436

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   15.255


  29 in total

Review 1.  Mechanism-based criteria to improve therapeutic outcomes in progressive multiple sclerosis.

Authors:  Heather Y F Yong; V Wee Yong
Journal:  Nat Rev Neurol       Date:  2021-11-03       Impact factor: 42.937

2.  Smoldering lesions in MS: if you like it then you should put a rim on it.

Authors:  Catarina Pinto; Melissa Cambron; Adrienn Dobai; Eva Vanheule; Jan W Casselman
Journal:  Neuroradiology       Date:  2021-09-09       Impact factor: 2.804

3.  A lymphocyte-microglia-astrocyte axis in chronic active multiple sclerosis.

Authors:  Martina Absinta; Dragan Maric; Marjan Gharagozloo; Thomas Garton; Matthew D Smith; Jing Jin; Kathryn C Fitzgerald; Anya Song; Poching Liu; Jing-Ping Lin; Tianxia Wu; Kory R Johnson; Dorian B McGavern; Dorothy P Schafer; Peter A Calabresi; Daniel S Reich
Journal:  Nature       Date:  2021-09-08       Impact factor: 69.504

4.  Does Ocrelizumab Limit Multiple Sclerosis Progression? Current Evidence from Clinical, MRI, and Fluid Biomarkers.

Authors:  Monica Margoni; Paolo Preziosa; Paola Tortorella; Massimo Filippi; Maria A Rocca
Journal:  Neurotherapeutics       Date:  2022-06-06       Impact factor: 6.088

Review 5.  Emerging therapies to target CNS pathophysiology in multiple sclerosis.

Authors:  Jiwon Oh; Amit Bar-Or
Journal:  Nat Rev Neurol       Date:  2022-06-13       Impact factor: 44.711

Review 6.  Cerebral Iron Deposition in Neurodegeneration.

Authors:  Petr Dusek; Tim Hofer; Jan Alexander; Per M Roos; Jan O Aaseth
Journal:  Biomolecules       Date:  2022-05-17

Review 7.  Novel Drugs in a Pipeline for Progressive Multiple Sclerosis.

Authors:  Klaudia Sapko; Anna Jamroz-Wiśniewska; Konrad Rejdak
Journal:  J Clin Med       Date:  2022-06-10       Impact factor: 4.964

8.  Peripheral Hemolysis in Relation to Iron Rim Presence and Brain Volume in Multiple Sclerosis.

Authors:  Nik Krajnc; Gabriel Bsteh; Gregor Kasprian; Tobias Zrzavy; Barbara Kornek; Thomas Berger; Fritz Leutmezer; Paulus Rommer; Hans Lassmann; Simon Hametner; Assunta Dal-Bianco
Journal:  Front Neurol       Date:  2022-06-29       Impact factor: 4.086

Review 9.  The role of glial cells in multiple sclerosis disease progression.

Authors:  Luke M Healy; Jo Anne Stratton; Tanja Kuhlmann; Jack Antel
Journal:  Nat Rev Neurol       Date:  2022-02-21       Impact factor: 44.711

10.  Quantitative susceptibility mapping versus phase imaging to identify multiple sclerosis iron rim lesions with demyelination.

Authors:  Weiyuan Huang; Elizabeth M Sweeney; Ulrike W Kaunzner; Yi Wang; Susan A Gauthier; Thanh D Nguyen
Journal:  J Neuroimaging       Date:  2022-03-09       Impact factor: 2.324

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.